Ludwig Maximilian University Of Munich
- Address
- Lindwurmstrasse 4, Ludwigsvorstadt-Isarvorstadt, 80337 Munich, Germany
Immune System Diseases (C20)
At Ludwig Maximilian University Of Munich, the pediatric department is advancing care for immune system diseases by testing a targeted biologic in children with inflammatory bowel conditions. The trials aim to assess how well the therapy induces remission, its safety profile, and its behavior in the body.
- Juvenile Psoriatic Arthritis
- Moderately to Severely Active Crohn's Disease
- Moderately to Severely Active Ulcerative Colitis
Researchers from the Dr. von Haunersches Kinderspital Kinderklinik und Kinderpoliklinik are enrolling young participants, with a team of sixteen investigators, to generate data that could improve future treatment options for these chronic conditions.
Immune System Processes (G12)
The site’s focus on immune system processes includes detailed evaluation of a biologic agent’s pharmacokinetics and long‑term safety in children. By monitoring how the drug interacts with the immune response, the studies seek to refine dosing strategies and ensure sustained benefits for pediatric patients.
- Juvenile Psoriatic Arthritis
- Moderately to Severely Active Crohn's Disease
- Moderately to Severely Active Ulcerative Colitis
With a commercial partner supporting the research, the multidisciplinary team at the university aims to generate robust evidence that can guide clinicians in managing immune‑mediated diseases in children.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 12 therapeutic areas and 15 of 64 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 60 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1GPOH gGmbH4active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC6trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ludwig Maximilian University Of Munich
lock Showing 1 of 34 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | Merck Sharp & Dohme LLC | Phase III | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 64 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 8 | Unknown | 2017-03-07 | 2023-10-06 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.